LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

32.47 0.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.51

Max

32.53

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5.8M

40M

Pardavimai

16M

200M

P/E

Sektoriaus vid.

11.558

35.664

Pelnas, tenkantis vienai akcijai

0.92

Pelno marža

19.839

Darbuotojai

268

EBITDA

3M

59M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+56.56% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

21M

2.1B

Ankstesnė atidarymo kaina

32.16

Ankstesnė uždarymo kaina

32.47

Naujienos nuotaikos

By Acuity

20%

80%

40 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-15 22:39; UTC

Įsigijimai, susijungimai, perėmimai

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

2025-09-15 16:43; UTC

Pagrindinės rinkos jėgos

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

2025-09-15 16:42; UTC

Pagrindinės rinkos jėgos

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

2025-09-15 16:35; UTC

Pagrindinės rinkos jėgos

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

2025-09-15 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-15 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

2025-09-15 23:34; UTC

Rinkos pokalbiai

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

2025-09-15 22:48; UTC

Rinkos pokalbiai

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

2025-09-15 22:12; UTC

Įsigijimai, susijungimai, perėmimai

CSL Expects Commercial Launch in 2029

2025-09-15 22:12; UTC

Įsigijimai, susijungimai, perėmimai

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

2025-09-15 22:11; UTC

Įsigijimai, susijungimai, perėmimai

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

2025-09-15 22:11; UTC

Įsigijimai, susijungimai, perėmimai

CSL to Have Right to Exercise Option Based on Phase 3 Data

2025-09-15 22:10; UTC

Įsigijimai, susijungimai, perėmimai

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

2025-09-15 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

2025-09-15 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

2025-09-15 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy to Buy 48,000 Net Acres in the Williston Core

2025-09-15 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

2025-09-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-09-15 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-15 19:29; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

2025-09-15 19:14; UTC

Rinkos pokalbiai

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

2025-09-15 18:16; UTC

Rinkos pokalbiai

Gold Powers to New High -- Market Talk

2025-09-15 18:05; UTC

Rinkos pokalbiai

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

2025-09-15 17:50; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

2025-09-15 17:10; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-15 17:10; UTC

Rinkos pokalbiai

S&P Expects Fed, BOC to Cut Rates -- Market Talk

2025-09-15 16:52; UTC

Rinkos pokalbiai

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

2025-09-15 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-15 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

56.56% į viršų

12 mėnesių prognozė

Vidutinis 50.71 USD  56.56%

Aukščiausias 70 USD

Žemiausias 33 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

7

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Very Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

40 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat